N-(4-mercaptobenzoyloxy)acetyl-morpholine | 262299-40-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-mercaptobenzoyloxy)acetyl-morpholine
• 英文别名: (2-Morpholin-4-yl-2-oxoethyl) 4-sulfanylbenzoate
• CAS: 262299-40-1
• 化学式: C₁₃H₁₅NO₄S
• 分子量: 281.332
• InChiKey: LZWMLEBBHDPXSW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  56.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-胍基苯甲酸甲烷磺酸盐 、 N-(4-mercaptobenzoyloxy)acetyl-morpholine 在 N,N'-二环己基碳二亚胺 作用下， 以 吡啶 为溶剂， 以48%的产率得到4-(4-Guanidino-benzoylsulfanyl)-benzoic acid 2-morpholin-4-yl-2-oxo-ethyl ester; compound with methanesulfonic acid
  参考文献：
  名称：

  Synthesis and structure-activity relationship study of the new set of trypsin-like proteinase inhibitors

  摘要：

  A new set of 25 trypsin-like proteinase inhibitors was prepared and the inhibiting activity on trypsin, thrombin, plasmin and urokinase was measured. The structure-activity relationship is discussed. High inhibiting activities were observed in 4-guanidinobenzoic acid esters only. The replacement of this moiety for N-formamidinyl-isonipecotic acid or an arginine moiety caused almost total loss of the activity. In the series of 4-guanidinobenzoic acid esters, any important influence of the ester-groups reactivity was observed. The trypsin-thrombin selectivity in the compounds with the guanidine-remote carboxylic function was also observed. (C) 1999 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(99)00123-3
• 作为产物：
  描述：

  N-(4-aminobenzoyloxy)acetyl-morpholine 在 盐酸 、 sodium nitrite 、 potassium ethyl dithiocarbonate 作用下， 以 水 为溶剂， 反应 0.25h， 以48%的产率得到N-(4-mercaptobenzoyloxy)acetyl-morpholine
  参考文献：
  名称：

  Synthesis and structure-activity relationship study of the new set of trypsin-like proteinase inhibitors

  摘要：

  A new set of 25 trypsin-like proteinase inhibitors was prepared and the inhibiting activity on trypsin, thrombin, plasmin and urokinase was measured. The structure-activity relationship is discussed. High inhibiting activities were observed in 4-guanidinobenzoic acid esters only. The replacement of this moiety for N-formamidinyl-isonipecotic acid or an arginine moiety caused almost total loss of the activity. In the series of 4-guanidinobenzoic acid esters, any important influence of the ester-groups reactivity was observed. The trypsin-thrombin selectivity in the compounds with the guanidine-remote carboxylic function was also observed. (C) 1999 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(99)00123-3

文献信息

• [EN] SMALL MOLECULE INHIBITORS OF DYRK1A AND USES THEREOF<br/>[FR] PETITES MOLÉCULES INHIBITRICES DE DYRK1A ET LEURS UTILISATIONS
  申请人：UNIV ARIZONA

  公开号：WO2017040993A1

  公开（公告）日：2017-03-09

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a benzimidazole or imidazopyridine structure which function as inhibitors of DYRK1A protein, and their use as therapeutics for the treatment of Alzheimer's disease, Down syndrome, glioblastoma, autoimmune diseases, inflammatory disorders (e.g., airway inflammation), and other diseases.